EUFOREA consensus on biologics for CRSwNP with or without asthma

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokkens, Wytske J., Lund, Valerie, Bachert, Claus, Mullol, Joaquim, Bjermer, Leif, Bousquet, Jean, Canonica, Giorgio W., Deneyer, Lauren, Desrosiers, Martin, Diamant, Zuzana, Han, Joseph, Heffler, Enrico, Hopkins, Claire, Jankowski, Roger, Joos, Guy, Knill, Andrew, Lee, Jivianne, Lee, Stella E., Mariën, Gert, Pugin, Benoit, Senior, Brent, Seys, Sven F., Hellings, Peter W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972984/
https://www.ncbi.nlm.nih.gov/pubmed/31090937
http://dx.doi.org/10.1111/all.13875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972984/
https://www.ncbi.nlm.nih.gov/pubmed/31090937
http://dx.doi.org/10.1111/all.13875

Ejemplares similares